Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy (NCT07106762)

🧪 Interventions in This Study

• Iza-bren (DRUG)
• Cisplatin (DRUG)
• Gemcitabine (DRUG)
• Carboplatin (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (163 Sites)

Showing the first 25 of 163 sites.

• Local Institution - 0167 — Gilbert, Arizona
• Local Institution - 0162 — Fullerton, California
• Palo Alto Center-Palo Alto Medical Foundation Research Institute — Palo Alto, California
• Sutter Health - Sutter Institute for Medical Research — Sacramento, California
• University of California Davis (UC Davis) Comprehensive Cancer Center — Sacramento, California
• Pacific Hematology Oncology Associates — San Francisco, California
• Sutter Santa Rosa — Santa Rosa, California
• Rocky Mountain Cancer Centers, LLP — Denver, Colorado
• Local Institution - 0245 — Dillon, Colorado
• Shaw Cancer Center — Edwards, Colorado
• Sibley Memorial Hospital — Washington D.C., District of Columbia
• Miami Cancer Institute at Baptist Health, Inc. — Miami, Florida
• University of Kentucky Chandler Medical Center — Lexington, Kentucky
• Johns Hopkins Hospital — Baltimore, Maryland
• Local Institution - 0195 — Boston, Massachusetts
• Karmanos Cancer Institute — Detroit, Michigan
• Local Institution - 0248 — Buffalo, New York
• Icahn School of Medicine at Mount Sinai — New York, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• Fairview Hospital — Cleveland, Ohio
• Cleveland Clinic — Cleveland, Ohio
• The James Outpatient Care West Campus — Columbus, Ohio
• Cleveland Clinic - Hillcrest Hospital — Mayfield Heights, Ohio
• Local Institution - 0141 — Portland, Oregon
• SCRI Oncology Partners — Nashville, Tennessee

📞 Contact the Study Coordinator

Phone: (855) 907-3286

Email: Clinical.Trials@bms.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Urothelial Cancer

• Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer — Chandler, Arizona
• A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations — Anchorage, Alaska
• A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer — Cleveland, Ohio
• A Genotype-Phenotype Urothelial Cancer Registry — Basking Ridge, New Jersey
• Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies — Bethesda, Maryland
• Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer — Los Angeles, California

Explore by condition: All Urothelial Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.